4.6 Review

Cancer Stem Cell-Associated Immune Microenvironment in Recurrent Glioblastomas

Journal

CELLS
Volume 11, Issue 13, Pages -

Publisher

MDPI
DOI: 10.3390/cells11132054

Keywords

glioblastoma; recurrence; cancer stem cell; immune microenvironment

Categories

Funding

  1. JSPS [20K21540, 18H02678, 18KK0433]
  2. Project for Cancer Research and Therapeutic Evolution (P-CREATE) from the Japan Agency for Medical Research and Development (AMED) [20cm0106264h0002]
  3. Nanken-Kyoten, TMDU

Ask authors/readers for more resources

Glioblastoma multiforme is an incurable tumor with a high relapse frequency. Cancer stem cells play a crucial role in therapy resistance and cancer recurrence by manipulating the microenvironment. However, there is limited research on recurrence, particularly regarding the tumor immune microenvironment.
Glioblastoma multiforme (GBM) is the most incurable tumor (due to the difficulty in complete surgical resection and the resistance to conventional chemo/radiotherapies) that displays a high relapse frequency. Cancer stem cells (CSCs) have been considered as a promising target responsible for therapy resistance and cancer recurrence. CSCs are known to organize a self-advantageous microenvironment (niche) for their maintenance and expansion. Therefore, understanding how the microenvironment is reconstructed by the remaining CSCs after conventional treatments and how it eventually causes recurrence should be essential to inhibit cancer recurrence. However, the number of studies focusing on recurrence is limited, particularly those related to tumor immune microenvironment, while numerous data have been obtained from primary resected samples. Here, we summarize recent investigations on the immune microenvironment from the viewpoint of recurrent GBM (rGBM). Based on the recurrence-associated immune cell composition reported so far, we will discuss how CSCs manipulate host immunity and create the special microenvironment for themselves to regrow. An integrated understanding of the interactions between CSCs and host immune cells at the recurrent phase will lead us to develop innovative therapies and diagnoses to achieve GBM eradication.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available